Soluble Fas ligand is a less potent inducer of poptosis than its membrane-bound form, and may be a mediator of inflammation as well as a death agonist (pages 31–36).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas
British Journal of Cancer Open Access 12 February 1999
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
Tanaka, M., Itai, T., Adachi, M. & Nagata, S. Downregulation of Fas ligand by shedding. Nature Med. 4, 31–36 (1998).
Medema, J.P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794–2804 (1997).
Duan, H. & Dixit, V.M. RAIDD is a new ‘death’ adaptor molecule. Nature 385, 86–89 (1997).
Yang, X., Khosravi-Far, R., Chang, H.Y. & Baltimore, D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89, 1067–1076 (1997).
Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes . J. Immunol. 158, 2303–2309 (1997).
Abreu-Martin, M.T., Vidrich, A., Lynch, D.H. & Targan, S.R. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155, 4147–4154 (1995).
Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943–3947 (1997).
Kang, S.-M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738–743 (1997).
Strasser, A., Harris, A.W., Huang, D.C.S., Krammer, P.H. & Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14, 6136–6147 (1995).
Lacronique, V. et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med. 2, 80–86 (1996).
Hahne, M. et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363–1366 (1996).
Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–194 (1997).
Klas, C., Debatin, K.-M., Jonker, R.R. & Krammer, P.H. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5, 625–630 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strasser, A., O'Connor, L. Fas ligand—cought between scylla and charybdis. Nat Med 4, 21–22 (1998). https://doi.org/10.1038/nm0198-021
Issue Date:
DOI: https://doi.org/10.1038/nm0198-021
This article is cited by
-
The kiss of death: promises and failures of death receptors and ligands in cancer therapy
Leukemia (2001)
-
FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas
British Journal of Cancer (1999)
-
Soluble fas antigen in serum of cancer patients
Bulletin of Experimental Biology and Medicine (1999)
